WORKSHOP TIME ZONE:
12th C1-Inhibitor Deficiency & Angioedema Workshop 3-6 June 2021
VIRTUAL EVENT
MAIN SPONSORS
SPONSORS

Final programme

in this version of the programme, only the presenter's name is indicated, please consider timing by Central European Summer Time titles below are shortened, point a title with your mouse to reveal it
Detailed instructions for speakers and poster presenters
____hello, we are
coming soon

Thursday, 3 June

17:30
Opening ceremony
  • Greeting of GuestsHenriette Farkas Hungary

  • Greeting of GuestsLilian Varga Hungary

  • Welcome performance

  • OPENING CEREMONY

18:25
Opening lectures
  • Kininogen(s) structure and function ’For HAE Patients’ awarded Allen P. Kaplan USA, introduced by Anthony Castaldo USA

19:25
    Chairs: Bruce Zuraw,
    József Dobó
    Opening lecture I

    The COVID-19 Bradykinin Storm — Confronting the COVID-19 pandemic with supercomputing, Explainable-AI and systems biology Daniel Jacobson USA

    Opening lecture II

    Global initiatives in HAE – The revision and update of the WAO/EAACI guideline for HAE and the ACARE networkMarcus Maurer Germany

    Opening lecture III

    Factor XII self-controlCoen Maas The Netherlands

21:25

Friday, 4 June

9:00
Opening lecture IV
Chairs: Christian Drouet,
Grzegorz Porebski

The integrative role of endothelial cells in bradykinin-mediated angioedema László Cervenak Hungary

9:45
Session I
Basic research, diagnostics
  • PHA-022121: Efficacy in a monkey bradykinin challenge model translated to human Anne Lesage Switzerland

  • Investigation of neutrophil granulocyte function in patients with Hereditary Angioedema Erika Kajdácsi Hungary

  • Detection of C1-inhibitor/C1-inhibitor antibody complexes and its connection with underlying diseases of acquired angioedema Zsófia Pólai Hungary

  • Activation of MASP-3 by PCSK6 links the complement and the proprotein convertase systems in the blood József Dobó Hungary

11:15 Break
11:45
Session II
Chairs:
Margarita López-Trascasa,
Péter Gál
Genetics
  • Preclinical studies of BMN 331 in mice and non-human primates demonstrate continuous, clinically meaningful production of C1-INH and phenotypic correction, warranting evaluation of this AAV-mediated gene therapy for treatment of Hereditary Angioedema in humans Jill Woloszynek United States

  • NTLA-2002: CRISPR-Mediated Gene Knockout of KLKB1 as a potential single-dose treatment for Hereditary Angioedema (HAE) James Butler United States

  • The constellation of SERPING1 variants associated with C1-INH-HAE Christian Drouet France

  • Understanding disease mechanisms of Hereditary Angioedema through RNA Seq transcriptome profiling Jonathan A Bernstein United States

13:15 Lunch break
14:15
Opening lecture V
Chairs: Avner Reshef,
Nihal Mete Gökmen

Tissue kallikrein, kinins and ACE (kininase II) in cardiovascular and renal diseases: the friendly side of kinins François Alhenc-Gelas France

15:00
Session III
Clinical aspects
  • Heart-rate variability evaluation during attacks in patients with Hereditary Angioedema due to C1-Inhibitor deficiency Francesca Perego Italy

  • Pregnancy outcome in patients with Hereditary Angioedema: A single center experience from North India Ankur Jindal India

  • Prodromes predict oncoming HAE attacks: results of a prospective study Iris Leibovich-Nassi Israel

  • New concepts in the classification of angioedema syndromes Avner Reshef Israel

  • Intravascular Bradykinin formation is modulated by the combined presence of pk, HK, C1INH, and PRCP Alvin Schmaier United States

16:45 Break
17:15
Poster session I
Chairs: Tomas Freiberger,
Marc Riedl
  • HAE Junior: A patient organization with a holistic approach Camelia Isaic Czech Republic
  • Lanadelumab efficacy is sustainable over time: Findings from the HELP Emel Aygören-Pürsün Germany
  • Reimbursement of the C1-Inhibitor esterase laboratory testing facilitates the early diagnosis of Hereditary Angioedema Noémi-Anna Bara Romania
  • Efficacy of subcutaneous C1-inhibitor long-term prophylaxis in C1-INH-HAE Ana Entrala Spain
  • Predicting clinical benefits of bradykinin B2 receptor ligands using the human umbilical vein contractility assay François Marceau Canada
  • Searching for genetic biomarkers for Hereditary Angioedema due to C1-inhibitor deficiency (C1-INH-HAE) Anastasios E. Germenis Greece
  • Laryngeal attack in Hereditary Angioedema in the emergency room: a case report Ana Karen Benítez-LimaMexico
  • Detailed long term follow-up of a patient with acquired angioedema due to C1-inhibitor deficiency Zsófia Pólai Hungary
  • A spectrum of Serping1 mutations and clinical characterisation of Czech Hereditary Angioedema patients Tomas Freiberger Czech Republic
  • Clinical and genetic diversity of Hereditary Angioedema in Latvia Adine Kanepa Latvia
18:45 'In memoriam'
  • 'In memoriam' Michael FrankAllen Kaplan USA

  • 'In memoriam' Jose Fabiani Alejandra Menendez Argentina

  • 'In memoriam' Marco Cicardi Andrea Zanichelli Italy

19:15
Virtual Budapest sightseeing


Budapest sightseeing video

20:15

Saturday, 5 June

9:00
Opening lecture VI
Chairs:
Emel Aygören-Pürsün,
Constance Katelaris

Novel types of Hereditary AngioedemaKonrad Bork Germany

9:45
Session IV
Treatment & Clinical trials
  • Recombinant human C1 esterase inhibitor as prophylaxis for idiopathic non-histaminergic angioedema Mehran Alizadeh Aghdam The Netherlands

  • Diagnosis of Hereditary Angioedema in Latin America is improving, however specific lab tests and therapies for many countries are not available Margarita Olivares Colombia

  • Long-term safety and efficacy of Berotralstat in Hereditary Angioedema (HAE): special considerations in patients transitioning from androgens Marcin Stobiecki Poland

  • Garadacimab, a novel monoclonal antibody targeting activated factor XII (FXIIa), prevents attacks in patients with Hereditary Angioedema (HAE) Markus Magerl Germany

  • Fast improvement of hereditary angioedema (HAE) attacks with the oral on-demand plasma kallikrein inhibitor KVD900: an analysis of the pharmacokinetic and pharmacodynamic profile of KVD900 and attack symptom severity during a double-blind, randomized phase 2 cross-over trial in patients with HAE type I and II Andrea Zanichelli Italy

11:30 Break
12:00
Session V
Chairs: Milos Jesenak,
Teresa Caballero
Case reports
  • ‘C1 inhibitor normal’ versus ‘C1 inhibitor deficient’ Hereditary Angioedema: A false dichotomy? Samantha Chan Australia

  • Covid19 in HAE patients – case series from a single centre John Dempster United Kingdom

  • Bariatric surgery in patients with Hereditary Angioedema due to C1-inhibitor deficiency Teresa Caballero Spain

  • Hereditary Angioedema: a case report Natalja Kurjane Latvia

  • Acquired Angioedema secondary to prostate cancer treated with lanadelumab Babak Aberumand Canada

13:45 Lunch break
14:45
Session VI
Chairs:
Anete Sevciovic Grumach,
Stephen Betschel
QoL & COVID-19
  • Angioedema Quality of Life Questionnaire (AE-QoL) - How to interpret its scores Karsten Weller Germany

  • Psychiatric and clinical characteristics of Hereditary Angioedema patients who experienced attacks during COVID-19 Nihal Gökmen Turkey

  • Use of subcutaneous human C1 esterase inhibitor concentrate as long -term prophylaxis therapy in patients with Hereditary Angioedema with C1 inhibitor deficiency during the COVID19 pandemic period Krasimira Baynova Spain

  • Latin-American Hae individuals with abnormal C1 Inhibitor infected by SARS Cov2 showed mild clinical manifestations Jairo Rodriguez Colombia

  • Quality of life on some Colombian Hae Patients Jairo Rodriguez Colombia

16:30 Break
17:00
Poster session II
Chairs: Alvin Schmaier,
Mauro Cancian
  • Impact of Lanadelumab in Hereditary Angioedema: A case series of 12 patients in Canada Aled Iaboni Canada
  • Living with HAE in Australia – Initial findings from a national observational study Constance Katelaris Australia
  • Angioedema and low C4 as initial manifestations leading to the diagnosis that is even rarer than HAE Sladjana Andrejevic Serbia
  • Novel genetic modifiers of the clinical phenotype in patients with Hereditary Angioedema due to C1 inhibitor deficiency Nina Rupar Slovenia
  • Overview of SERPING1 variations identified in Hungarian patients with Hereditary Angioedema Dorottya Csuka Hungary
  • SERPING1 gene promoter variation in Turkish patient with HAE Aycan Aşik Turkey
  • Real-world effectiveness and disease/treatment management associated with lanadelumab long-term prophylaxis in HAE: design for a retrospective chart review Markus Magerl Germany
  • Burden of illness and treatment patterns in patients with Hereditary Angioedema type I and II: A retrospective observational chart review Henriette Farkas Hungary
  • Can HAE patients with C1INH deficiency be completely alleviated from disease symptoms? Yes, we can! Hilary Longhurst New Zealand
  • HAE treatment – Single or multiple pathways to the rescue? Anna Valerieva Bulgaria
  • Successful prophylactic recombinant human C1-esterase inhibitor for the treatment of Idiopathic non-histaminergic angioedema (iNHAE): a case report Mehran Alizadeh Aghdam The Netherlands
18:30
Virtual Gala dinner


Sunday, 6 June

9:00
Session VII
Chairs: Hilary Longhurst,
Yuxiang Zhi
National surveys
  • A national audit of Hereditary and Acquired Angioedema in New Zealand 2019 Ke Li Chow New Zealand

  • Characterization of Hereditary Angioedema due to mutations in the F12 gene in seven Spanish families Francisca Vílchez-Sánchez Spain

  • Clinical and therapeutic characteristics of adult patients with idiopathic angioedema Mehran Alizadeh Aghdam The Netherlands

  • The characteristics and the incidence of upper airway edema in patients with Hereditary and acquired angioedema with C1 inhibitor deficiency Zsuzsanna Balla Hungary

  • Diagnosing pediatric patients with Hereditary C1-inhibitor deficiency – experience from the Hungarian Angioedema Center of reference and excellence Noémi Andrási Hungary

  • Clinical and demographic characteristics of patients with Hereditary Angioedema in Canada Erika Lee Canada

  • This is HAE International Anthony Castaldo United States

    This is HAE International Henrik Balle Boysen Denmark

11:00 Break
11:30
’Grant for Young Investigators’ Ceremony
Closing remarks
  • Closing remarks Anastasios E. Germenis Greece


CLOSING
CEREMONY

Invited speakers

WE ARE TOGETHER!

BEHIND THE STAGES

MORE
LESS

Deadlines

8 APRIL
EXTENDED ABSTRACT SUBMISSIONCLOSED
15 APRIL
EARLY BIRD
FEECLOSED
3-6 JUNE WORKSHOP
DAYS

FOLLOW US IN THE SOCIAL MEDIA

Our preliminary scientific programme is available at our website. 👨‍💼 It's gonna be LEGEN... wait for it... DARY!!!...

Közzétette: Diamond Congress Kft. – 2021. május 4., kedd
FINANCE

Registration fees

The discounted fee was available before 15 April.
STANDARD FEE

250 €

190 €   INCLUDING:
  • presentations
  • abstracts
  • exhibition area
  • live socialising area
  • and tons of fun...
STUDENT FEE

FREE

100 € FOR PRESENTERS INCLUDING:
  • presentations
  • abstracts
  • exhibition area
  • live socialising area
  • and tons of fun...
12TH C1-inhibitor Deficiency & Angioedema Workshop © 2021 - CONTACT US!
background photos are a courtesy of Ensana Hotel Margaret Island
3-6 June 2021 - virtual event
the significance and mystery
of the number
do you know another fun fact about '12'? Please, send it to us!
move your mouse over the text to stop sliding